Samrat Pharmachem Limited (BOM:530125)

Market Cap	647.14M
Revenue (ttm)	2.89B
Net Income (ttm)	15.69M
Shares Out	3.09M
EPS (ttm)	5.08
PE Ratio	41.25
Forward PE	n/a
Dividend	1.00 (0.47%)
Ex-Dividend Date	Sep 18, 2025

Volume	362
Average Volume	1,670
Open	217.45
Previous Close	210.35
Day's Range	206.15 - 217.45
52-Week Range	206.00 - 425.00
Beta	-0.45
RSI	34.36
Earnings Date	Feb 13, 2026

About Samrat Pharmachem

Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical,...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 28
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530125

Financial Performance

In 2024, Samrat Pharmachem's revenue was 2.86 billion, an increase of 1.52% compared to the previous year's 2.82 billion. Earnings were 71.12 million, an increase of 228.87%.